EGFR and non-small cell lung carcinoma: Furthermore, osimertinib has recently shown clinical benefit as a first-line treatment for EGFR mutation-positive NSCLC compared with a standard of care including first-generation EGFR-TKIs (erlotinib or gefitinib) [5].